Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Recurring cancer children (ADVL0212 NCT00053963) - Reporting Period Worksheet cancer (NCT00053963)

- 22.03.15 - 1 Formulaire, 5 Groupes Item, 58 Eléments de données, 1 Langue

Groupes Item: Header, Patient characteristics, Concomitant Medication, Patient status, Adverse event

ADVL0212: Reporting Period Worksheet FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1EC15B1-1989-311F-E034-0003BA12F5E7

Eligibility Brain Cancer NCT01065805

- 20.08.19 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01065805

dbGaP phs000725 Rare Cancer Tumors Project - pht003882.v2.p1

- 06.01.23 - 9 Formulaires, 1 Groupe Item, 5 Eléments de données, 1 Langue

Groupe Item: pht003882

Principal Investigator: David A. Wheeler, PhD, Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA MeSH: Neoplasms,Brain Neoplasms,Germinoma,Neoplasms, Germ Cell and Embryonal,Endodermal Sinus Tumor,Teratoma,Carcinoma, Embryonal,Choriocarcinoma,Polycythemia Vera,Craniopharyngioma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000725 A large proportion of common cancers affecting patients around the world have been selected for comprehensive cancer genome studies. Further efforts will be needed to tackle the remaining tumor types, including the rare forms of cancers. Although rare, these cancers tend to be more aggressive and fast growing with an early recurrence following initial chemotherapy and poor prognosis. Besides, patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer. While sample collection is a major challenge, the integrated genomic analyses would identify novel causative genes in these rare cancers, shed new light on the biology of the rare cancers, as well as guide novel targeted cancer therapies. Through efficient collaboration, the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine (BCM) has collected/is expected to collect 20 different types of rare cancers, 15-30 cases each. Whole-exome sequencing and high-resolution SNP array analysis were/will be performed for all cases and whole-genome sequencing was designed for a selected subset of the cases. *The Rare Cancer Tumors Cohort is utilized in the following dbGaP sub-studies.* To view genotypes, other molecular data, and derived variables collected in this sub-study, please click on the following sub-study below or in the "Sub-studies" section of this top-level study page phs000725 Rare Cancer Tumors Cohort.- phs000754 Intracranial Germ Cell Tumors - phs000861 Craniopharyngioma Tumors - phs000859 Sezary Syndrome Genomic Analysis

Eligibility

1 Groupe Item 1 Élément de données

Afficher plus

HIV Cancer Sunitinib NCT00890747 AMC-061 - Response Evaluation Form (R61)

- 24.06.17 - 1 Formulaire, 7 Groupes Item, 35 Eléments de données, 1 Langue

Groupes Item: Header Module, Complete Response, Morphologic Complete Remission, Complete Response, Unconfirmed, Complete Response with Incomplete Bone Marrow Recovery, PR, Progressive Disease

AMC-061 Response Evaluation Form (R61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Sunitinib in HIV with Cancer NCT00890747 AMC-061 - HIV Viral Load Form (F40)

- 20.06.17 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue

Groupes Item: Header Module, HIV Viral Load

AMC-061 HIV Viral Load Form (F40) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Sunitinib in HIV with Cancer NCT00890747 AMC-061 - Off Study Summary Form (F50)

- 20.06.17 - 1 Formulaire, 1 Groupe Item, 4 Eléments de données, 1 Langue

Groupe Item: Off-Study Summary

AMC-061 Off Study Summary Form (F50) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV Cancer Sunitinib NCT00890747 AMC-061 - Missed Visit Form (F35)

- 12.06.17 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue

Groupes Item: Header Module, Missed Visit Information

AMC-061 Missed Visit Form (F35) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV Cancer Sunitinib NCT00890747 AMC-061 - Pharmacokinetics Form (P61)

- 12.06.17 - 1 Formulaire, 2 Groupes Item, 5 Eléments de données, 1 Langue

Groupes Item: Header Module, Pharmacodynamics

AMC-061 Pharmacokinetics Form (P61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV Cancer Sunitinib NCT00890747 AMC-061 - Protocol Deviation Form (DEV)

- 12.06.17 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue

Groupes Item: Header Module, Protocol Deviation

AMC-061 Protocol Deviation Form (DEV) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

HIV with Cancer Baseline AMC-061 NCT00890747 - Baseline Evaluation Form HIV with Cancer NCT00890747

- 20.05.15 - 1 Formulaire, 4 Groupes Item, 19 Eléments de données, 1 Langue

Groupes Item: Header Module, SOLID TUMOR/LYMPHOMA ASSESSMENT, KAPOSI'S SARCOMA ASSESSMENT, HEMATOLOGIC MALIGNANCY ASSESSMENT

AMC-061 Baseline Evaluation Form (B61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy NCT00890747 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=715BD918-9168-2975-E040-BB89AD434610

Toxicity - Brain Cancer - Adverse Event Form - 2263172v3.0 - Brain Cancer - Adverse Event Form

- 09.01.15 - 1 Formulaire, 4 Groupes Item, 23 Eléments de données, 1 Langue

Groupes Item: CRF Header, Brain: Form Administration, Brain: Adverse Events, Comments

Brain Cancer - Adverse Event Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DE93FBC6-0592-249A-E034-0003BA12F5E7

Treatment - Brain Cancer - Treatment by Cycle Form - 2287531v3.0 - Brain Cancer - Treatment by Cycle Form

- 09.01.15 - 1 Formulaire, 7 Groupes Item, 48 Eléments de données, 1 Langue

Groupes Item: CRF Header, Brain: Treatment Reporting Interval, Brain: Treatment Cycle Information - Clinical Evaluation Follow-up, Brain: Treatment Cycle Information - Systemic Therapy, Brain: Treatment Cycle Information - Concomitant Therapy, Brain: Treatment Schedule - Non-Protocol Therapy, Comments

Brain Cancer - Treatment by Cycle Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E51F0AB1-37FF-4133-E034-0003BA3F9857

Mots-clés

Table des matières

Modèles de données sélectionnés

Recurring cancer children (ADVL0212 NCT00053963) - Reporting Period Worksheet cancer (NCT00053963)

Eligibility Brain Cancer NCT01065805

dbGaP phs000725 Rare Cancer Tumors Project - pht003882.v2.p1

pht003885.v2.p1

pht003886.v2.p1

pht004475.v2.p1

pht004476.v2.p1

pht004585.v2.p1